 <h1>Interferon beta-1b Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of interferon beta-1b include:</b> uterine hemorrhage, abdominal pain, antibody development, asthenia, chest pain, decreased white blood cell count, fever, flu-like symptoms, headache, hypertonia, increased serum alanine aminotransferase, injection site reaction, insomnia, leukopenia, myalgia, pain, anxiety, arthralgia, constipation, diarrhea, disorder of integument, dizziness, dyspepsia, lymphocytopenia, myasthenia, nausea, peripheral edema, skin rash, urinary urgency, abnormal absolute neutrophil count, chills, and inflammation at injection site. <b>Other side effects include:</b> alopecia, dyspnea, hypertension, lower limb cramp, lymphadenopathy, palpitations, tachycardia, tissue necrosis at injection site, impotence, nervousness, peripheral vascular disease, urinary frequency, vasodilation, weight gain, malaise, and diaphoresis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to interferon beta-1b: subcutaneous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, interferon beta-1b may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking interferon beta-1b:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>break in the skin at the injection site, with blue-black discoloration, swelling, or drainage of fluid</li>
<li>flu-like symptoms including chills, fever, generalized feeling of discomfort or illness, increased sweating, and muscle pain</li>
<li>headache or migraine</li>
<li>hives, itching, or swelling at the injection site</li>
<li>irregular or pounding heartbeat</li>
<li>redness, pain, or feeling of heat at the injection site</li>
<li>stuffy nose</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bloody or cloudy urine</li>
<li>breast pain</li>
<li>changes in vision</li>
<li>cold hands and feet</li>
<li>difficult, burning, or painful urination</li>
<li>fast or racing heartbeat</li>
<li>frequent urge to urinate</li>
<li>pain</li>
<li>pelvic pain</li>
<li>swollen glands</li>
<li>troubled breathing</li>
<li>unusual weight gain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abnormal growth in the breast</li>
<li>benign lumps in the breast</li>
<li>bleeding problems</li>
<li>bloating or swelling</li>
<li>changes in menstrual periods</li>
<li>confusion</li>
<li>convulsions (seizures)</li>
<li>cyst (abnormal growth filled with fluid or semisolid material)</li>
<li>decreased sexual ability in males</li>
<li>dry, puffy skin</li>
<li>feeling cold</li>
<li>hyperactivity</li>
<li>increased muscle tone</li>
<li>increased urge to urinate</li>
<li>loss of memory</li>
<li>mental depression with thoughts of suicide</li>
<li>problems with speaking</li>
<li>red, itching, or swollen eyes</li>
<li>swelling of the front part of the neck</li>
<li>unusual weight loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of interferon beta-1b may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>loss of voice</li>
<li>menstrual pain or other changes</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>drowsiness</li>
<li>hair loss</li>
<li>vomiting</li>
</ul><p>
<!-- end subcutaneous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to interferon beta-1b: subcutaneous powder for injection</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p>
<p>Rare (Less than 0.1%): Cardiomyopathy, congestive heart failure, palpitations, arrhythmia, tachycardia, vasodilatation, chest pain, hypertension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin rashes (25%), increased sweating</p>
<p><b>Common</b> (1% to 10%): Contusion, pruritus, erythematous rash, maculopapular rash, night sweats</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, allergic dermatitis, erythema, urticaria</p>
<p><b>Rare</b> (0.01% to 0.1%): Skin ulceration/necrosis at the site of injection, Quincke's edema (angioedema), erythema multiforme, Stevens-Johnson syndrome </p>
<p><b>Very rare</b> (less than 0.01%): Calcified subcutaneous nodules, psoriasis, periungual and nail alterations</p>
<p><b>Frequency not reported</b>: Rash vesicular<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hypothyroidism, hyperthyroidism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (27%), diarrhea (17%), constipation (12%), vomiting (10%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain</p>
<p><b>Frequency not reported</b>: Dry mouth, dyspepsia, pancreatitis<sup>[Ref]</sup></p><h3>General</h3><p>Influenza-like symptoms (e.g., myalgia, fever, chills, sweating, asthenia, headache, nausea) are the most common adverse reactions.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (19%), cystitis (11%)</p>
<p><b>Frequency not reported</b>: Metrorrhagia, menorrhagia, urinary incontinence, increase in the frequency of micturition<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (14%), leukopenia (11%), neutropenia, thrombocytopenia, anemia </p>
<p><b>Common</b> (1% to 10%): Neutrophil count decreased, hematocrit decreased, blood potassium increased, blood urea nitrogen increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Platelet count decreased</p>
<p>Rare (Less than 0.1%): Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, </p>
<p><b>Frequency not reported</b>: Pancytopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase increased (26%), aspartate aminotransferase increased (16%)</p>
<p><b>Common</b> (1% to 10%): Gamma-glutamyl-transferase increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatitis (with or without icterus)</p>
<p>Rare (Less than 0.1%): Hepatic failure, autoimmune hepatitis </p>
<p><b>Frequency not reported</b>: Elevation of hepatic transaminases (SGPT and SGOT), bilirubinemia, jaundice<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Rare (Less than 0.1%): Anaphylactic reactions</p>
<p><b>Frequency not reported</b>: Other allergic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Influenza-like symptoms (49%)</p>
<p><b>Frequency not reported</b>: Systemic lupus erythematosus, anaphylactic reaction, anaphylactic shock, hypersensitivity reactions (angioedema, dyspnea, urticaria, rash, pruritic rash)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site erythema (62%), injection site pain (15%), injection site pruritus (13%), injection site bruising</p>
<p><b>Common</b> (1% to 10%): Injection site edema, injection site warmth, injection site hematoma, injection site rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Injection site infections (which could be severe)</p>
<p>Rare (Less than 0.1%): Injection site cellulitis (which could be severe) </p>
<p><b>Frequency not reported</b>: Injection site abscess, injection site reaction, injection site inflammation, injection site necrosis, injection site bleeding<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Weight decreased, weight increased<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (19%), back pain (20%), pain in extremity (19%), arthralgia (16%), muscular weakness (12%), muscle spasms (10%)</p>
<p><b>Common</b> (1% to 10%): Muscle spasticity, muscle cramp, neck pain, arthralgia, muscle stiffness, musculoskeletal stiffness</p>
<p><b>Rare</b> (0.01% to 0.1%): Drug induced lupus erythematosus </p>
<p><b>Frequency not reported</b>: Arthritis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (67%), dizziness (16%), paresthesia (12%)</p>
<p><b>Common</b> (1% to 10%): Hypoesthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Facial hypoesthesia</p>
<p><b>Frequency not reported</b>: Neurological symptoms, syncope, hypertonia, seizures, migraine<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (45%), asthenia (24%), pain (23%), fever (20%), chills (19%)</p>
<p><b>Common</b> (1% to 10%): Fatigue, malaise, hyperthermia, vertigo</p>
<p><b>Frequency not reported</b>: Tachyphylaxis, sudden hearing loss, tinnitus (ototoxic effects resolved 7 to 14 days after discontinuation of the drug)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression/suicidal ideation, insomnia, somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Anxiety</p>
<p><b>Frequency not reported</b>: Suicide attempt, suicide, psychosis, anxiety, confusion, emotional lability, anhedonia, psychotic thoughts, mood disturbances, hypersexuality, aggressive behavior, panic attacks<sup>[Ref]</sup></p><h3>Renal</h3><p>Rare (Less than 0.1%): Nephrotic syndrome, glomerulosclerosis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Oropharyngeal pain (28%), nasopharyngitis (24%), upper respiratory tract infection (21%), cough (16%), sinusitis (14%)</p>
<p><b>Common</b> (1% to 10%): Rhinorrhea, bronchitis</p>
<p><b>Rare</b> (0.01% to 0.1%): Dyspnea </p>
<p><b>Frequency not reported</b>: Pulmonary arterial hypertension<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about interferon beta-1b</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: interferons</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Interferon beta-1b Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Betaseron, Extavia</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</li>
<li>Colorectal Cancer</li>
<li>Multiple Sclerosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to interferon beta-1b: subcutaneous powder for injection</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p><p>Rare (Less than 0.1%): Cardiomyopathy, congestive heart failure, palpitations, arrhythmia, tachycardia, vasodilatation, chest pain, hypertension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin rashes (25%), increased sweating</p><p><b>Common</b> (1% to 10%): Contusion, pruritus, erythematous rash, maculopapular rash, night sweats</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, allergic dermatitis, erythema, urticaria</p><p><b>Rare</b> (0.01% to 0.1%): Skin ulceration/necrosis at the site of injection, Quincke's edema (angioedema), erythema multiforme, Stevens-Johnson syndrome </p><p><b>Very rare</b> (less than 0.01%): Calcified subcutaneous nodules, psoriasis, periungual and nail alterations</p><p><b>Frequency not reported</b>: Rash vesicular<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hypothyroidism, hyperthyroidism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (27%), diarrhea (17%), constipation (12%), vomiting (10%)</p><p><b>Common</b> (1% to 10%): Abdominal pain</p><p><b>Frequency not reported</b>: Dry mouth, dyspepsia, pancreatitis<sup>[Ref]</sup></p><h3>General</h3><p>Influenza-like symptoms (e.g., myalgia, fever, chills, sweating, asthenia, headache, nausea) are the most common adverse reactions.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (19%), cystitis (11%)</p><p><b>Frequency not reported</b>: Metrorrhagia, menorrhagia, urinary incontinence, increase in the frequency of micturition<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (14%), leukopenia (11%), neutropenia, thrombocytopenia, anemia </p><p><b>Common</b> (1% to 10%): Neutrophil count decreased, hematocrit decreased, blood potassium increased, blood urea nitrogen increased</p><p><b>Uncommon</b> (0.1% to 1%): Platelet count decreased</p><p>Rare (Less than 0.1%): Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, </p><p><b>Frequency not reported</b>: Pancytopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase increased (26%), aspartate aminotransferase increased (16%)</p><p><b>Common</b> (1% to 10%): Gamma-glutamyl-transferase increased</p><p><b>Uncommon</b> (0.1% to 1%): Hepatitis (with or without icterus)</p><p>Rare (Less than 0.1%): Hepatic failure, autoimmune hepatitis </p><p><b>Frequency not reported</b>: Elevation of hepatic transaminases (SGPT and SGOT), bilirubinemia, jaundice<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Rare (Less than 0.1%): Anaphylactic reactions</p><p><b>Frequency not reported</b>: Other allergic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Influenza-like symptoms (49%)</p><p><b>Frequency not reported</b>: Systemic lupus erythematosus, anaphylactic reaction, anaphylactic shock, hypersensitivity reactions (angioedema, dyspnea, urticaria, rash, pruritic rash)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site erythema (62%), injection site pain (15%), injection site pruritus (13%), injection site bruising</p><p><b>Common</b> (1% to 10%): Injection site edema, injection site warmth, injection site hematoma, injection site rash</p><p><b>Uncommon</b> (0.1% to 1%): Injection site infections (which could be severe)</p><p>Rare (Less than 0.1%): Injection site cellulitis (which could be severe) </p><p><b>Frequency not reported</b>: Injection site abscess, injection site reaction, injection site inflammation, injection site necrosis, injection site bleeding<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Weight decreased, weight increased<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (19%), back pain (20%), pain in extremity (19%), arthralgia (16%), muscular weakness (12%), muscle spasms (10%)</p><p><b>Common</b> (1% to 10%): Muscle spasticity, muscle cramp, neck pain, arthralgia, muscle stiffness, musculoskeletal stiffness</p><p><b>Rare</b> (0.01% to 0.1%): Drug induced lupus erythematosus </p><p><b>Frequency not reported</b>: Arthritis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (67%), dizziness (16%), paresthesia (12%)</p><p><b>Common</b> (1% to 10%): Hypoesthesia</p><p><b>Uncommon</b> (0.1% to 1%): Facial hypoesthesia</p><p><b>Frequency not reported</b>: Neurological symptoms, syncope, hypertonia, seizures, migraine<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (45%), asthenia (24%), pain (23%), fever (20%), chills (19%)</p><p><b>Common</b> (1% to 10%): Fatigue, malaise, hyperthermia, vertigo</p><p><b>Frequency not reported</b>: Tachyphylaxis, sudden hearing loss, tinnitus (ototoxic effects resolved 7 to 14 days after discontinuation of the drug)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression/suicidal ideation, insomnia, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Anxiety</p><p><b>Frequency not reported</b>: Suicide attempt, suicide, psychosis, anxiety, confusion, emotional lability, anhedonia, psychotic thoughts, mood disturbances, hypersexuality, aggressive behavior, panic attacks<sup>[Ref]</sup></p><h3>Renal</h3><p>Rare (Less than 0.1%): Nephrotic syndrome, glomerulosclerosis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Oropharyngeal pain (28%), nasopharyngitis (24%), upper respiratory tract infection (21%), cough (16%), sinusitis (14%)</p><p><b>Common</b> (1% to 10%): Rhinorrhea, bronchitis</p><p><b>Rare</b> (0.01% to 0.1%): Dyspnea </p><p><b>Frequency not reported</b>: Pulmonary arterial hypertension<sup>[Ref]</sup></p><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA. </p><h2>More about interferon beta-1b</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: interferons</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Interferon beta-1b Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</li>
<li>Colorectal Cancer</li>
<li>Multiple Sclerosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>